BOSULIF

Consider BOSULIF for your patients with Ph+ CML with resistance or intolerance to prior therapy1

TKI=tyrosine kinase inhibitor.

References
  1. BOSULIF Prescribing Information. New York, NY: Pfizer Inc.
  2. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (Guidelines®) for Chronic Myeloid Leukemia V.1.2018. © National Comprehensive Cancer Network, Inc. 2017. All rights reserved. Accessed August 8, 2017. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content or its use or application and disclaims any responsibility for its use or application in any way.